Free Trial
NASDAQ:TLSA

Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Tiziana Life Sciences logo
$0.57 +0.00 (+0.72%)
As of 03:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Tiziana Life Sciences Stock (NASDAQ:TLSA)

Advanced

Key Stats

Today's Range
$0.55
▼
$0.61
50-Day Range
$0.57
▼
$1.19
52-Week Range
$0.55
▼
$1.90
Volume
474,631 shs
Average Volume
401,590 shs
Market Capitalization
$73.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Tiziana Life Sciences is a biotechnology company developing treatments for inflammatory and neurodegenerative diseases. Its development work has focused on foralumab, a fully human monoclonal antibody that targets CD3, a protein found on T cells involved in the immune response.

The company is investigating an intranasal formulation of foralumab for conditions including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. These uses remain investigational, and foralumab is not an approved treatment.

Tiziana has concentrated its research and development on advancing this immune-modulating therapy through clinical studies.

AI Generated. May Contain Errors.

Tiziana Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

TLSA MarketRank™: 
0.48402068691 of 5 stars

Tiziana Life Sciences scored higher than 10% of companies evaluated by MarketBeat, and ranked 852nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tiziana Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Tiziana Life Sciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Tiziana Life Sciences' stock forecast and price target.
    • Percentage of Shares Shorted

      3.82% of the float of Tiziana Life Sciences has been sold short.
    • Short Interest Ratio / Days to Cover

      Tiziana Life Sciences has a short interest ratio ("days to cover") of 6.98.
    • Change versus previous month

      Short interest in Tiziana Life Sciences has recently increased by 4.71%, indicating that investor sentiment is decreasing.
    • Dividend Yield

      Tiziana Life Sciences does not currently pay a dividend.

    • Dividend Growth

      Tiziana Life Sciences does not have a long track record of dividend growth.

    • News Sentiment

      Tiziana Life Sciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
    • News Coverage This Week

      MarketBeat has tracked 10 news articles for Tiziana Life Sciences this week, compared to 2 articles on an average week.
    • Insider Buying vs. Insider Selling

      In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Tiziana Life Sciences has minimal institutional ownership at this time.

    • Read more about Tiziana Life Sciences' insider trading history.
    Receive TLSA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    TLSA Stock News Headlines

    A Nasdaq drone company just landed a deal with a Philippine billionaire's group
    A Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue. The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more. It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines.tc pixel
    BTIG Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)
    See More Headlines

    TLSA Stock Analysis - Frequently Asked Questions

    Tiziana Life Sciences' stock was trading at $1.49 at the start of the year. Since then, TLSA shares have decreased by 61.7% and is now trading at $0.57.

    Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

    Tiziana Life Sciences' top institutional investors include Marshall Wace LLP (0.93%), Mid American Wealth Advisory Group Inc. (0.35%) and China Universal Asset Management Co. Ltd..
    View institutional ownership trends
    .

    Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Tesla (TSLA), NVIDIA (NVDA), NIO (NIO), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA).

    Company Calendar

    Today
    11/16/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Biotechnology
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:TLSA
    CIK
    1723069
    Fax
    N/A
    Employees
    10
    Year Founded
    2013

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    N/A
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    N/A
    Price / Book
    N/A

    Miscellaneous

    Outstanding Shares
    127,260,000
    Free Float
    76,584,000
    Market Cap
    $73.94 million
    Optionable
    Optionable
    Beta
    0.49

    Social Links

    The 7 Best High-Yield Dividend Stocks for 2027 Cover

    Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

    Get This Free Report

    This page (NASDAQ:TLSA) was last updated on 11/16/2026 by MarketBeat.com Staff.
    From Our Partners